DOI: 10.4244/EIJV15I13A211

Advocacy: speaking on behalf of our patients

Andreas Baumbach1, MD, PhD

What role should a learned society play in advocacy? And what exactly can we do?

The mission of the European Society of Cardiology (ESC) is to “reduce the burden of cardiovascular disease”. We aligned the mission of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) to “reduce the burden of cardiovascular disease by percutaneous cardiovascular interventions”. The most visible activities of the large EAPCI community are in the field of education and training: we all know the courses EuroPCR and PCR London Valves, which annually teach and train more than 15,000 participants locally and many more through online media. We have the EAPCI/PCR Fellows Course for the next generation of young interventional cardiologists. Less known are our activities in the field of advocacy.

We believe that, in parallel with the ESC Advocacy efforts, which have recently included lobby work for more funding of cardiovascular research from Brussels, there is a need to speak and act on behalf of our patients suffering from conditions that can be treated by interventional techniques. In this article I would like to highlight three major EAPCI initiatives of recent years.

The “For life” initiatives started with Stent for Life, the first EAPCI programme which aimed to bring guideline-recommended ST-elevation myocardial infarction (STEMI) treatment to countries and areas where there was little provision of primary PCI1. Country champions worked together with the steering group to assess practice and implement improvements, leading to increased access to life-saving treatments for patients suffering an acute myocardial infarction. The rest is history! The concept was very successful, and continues to spread, now as a global movement in collaboration with our partner PCR under the name “Stent – Save a Life!”.

The same principle was applied when it became apparent that transcatheter aortic valve implantation (TAVI) showed a wide variation in availability across Europe to patients in need. The Valve for Life initiative was founded and successfully improved access to TAVI in the three pilot countries – Poland, France and Portugal2. We will be looking to engage a fourth country in 2020 and will report on the results of this successful programme.

Information about the penetration of treatment in individual regions and countries is essential. A comparison between countries gives an opportunity to argue for improvement and harmonisation and helps when lobbying for a better access and improved infrastructure; hence, the EAPCI White Book 2016 was created. In a unique survey, 16 countries in Europe contributed detailed numbers on healthcare resources with a focus on interventional cardiology, procedures and resources for percutaneous coronary interventions, and procedures and resources for structural heart interventions. The paper illustrates the still very large heterogeneity of numbers of procedures and access to life-saving treatments across our member countries. The second edition, now under the name EAPCI Atlas, is underway with increased capture of data. We will be able not only to spotlight activity and infrastructure every two years, but also, and importantly, to show dynamic developments in procedures, and their relationship to new evidence and guideline recommendations.

Finally, as the third example of EAPCI advocacy work, the new patient focus programme requires a mention. Launched in 2018, this initiative focuses on the direct interaction with our patients3. We have identified areas of need4 and started work on the involvement of patients in decision making, research, and, importantly, created useful tools for our practice. Led by Fina Mauri and Robert Byrne, we are developing Patient-Reported Outcome Measures (PROMS), Patient-Reported Experience Measures (PREMS), and a media-based tool to aid consent for coronary procedures. We expect to be able to present the results of these initiatives in early 2020 and look forward to their implementation in practice.

The work on advocacy will continue. We hope to attract support from you along the way and invite you to join in the efforts!

Volume 15 Number 13
Jan 17, 2020
Volume 15 Number 13
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV15I5A74 Aug 29, 2019
Working across borders: EAPCI and the National Societies
Baumbach A
free

10.4244/EIJV7I8A142 Dec 30, 2011
Rayonnement…
Fajadet J
free

10.4244/EIJV10I4A75 Aug 19, 2014
Focus on EAPCI committees
Windecker S
free

10.4244/EIJV8I10A174 Feb 22, 2013
EAPCI: active collaboration advancing education and innovation
Fajadet J
free

10.4244/EIJV10I5A96 Sep 28, 2014
The role of the EAPCI in producing scientific documents and articles
Windecker S
free

10.4244/EIJV7I5A87 Sep 30, 2011
A sure vision for the future
Fajadet J
free

10.4244/EIJV8I5A83 Sep 28, 2012
The “Valve” Season is upon us
Fajadet J
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved